Sarepta Therapeutics (NASDAQ:SRPT) Upgraded at HC Wainwright
HC Wainwright upgraded shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) from a sell rating to a neutral rating in a report issued on Wednesday, Marketbeat reports. HC Wainwright currently has $75.00 price target on the biotechnology company’s stock. A number of other research firms have also recently commented on SRPT. Deutsche Bank Aktiengesellschaft lowered […]
More Stories
Leading Employment Indicator Suggests Job Growth in Near Term
By Naveen Athrappully A Conference Board indicator of future employment shifts in the United States went up in March, signaling...
Leading Employment Indicator Suggests Job Growth in Near Term
By Naveen Athrappully A Conference Board indicator of future employment shifts in the United States went up in March, signaling...
More Than 900 Illegal Immigrants Charged With Immigration Crimes in 1 Week: DOJ
By Aldgra Fredly More than 900 illegal immigrants were charged with immigration-related offenses during the first week of April, the...
Idaho Governor Signs Bill Banning Businesses, Schools From Requiring Medical Procedures
By Zachary Stieber Idaho Gov. Brad Little has signed legislation that bans businesses and schools from requiring customers, employees, and...
FBI Investigates Vandalism of Tesla Charging Station in Washington State
By Bill Pan The Federal Bureau of Investigation (FBI) is investigating an incident that severely damaged a Tesla Supercharger station...
US Stock Indexes Skyrocket Following Trump’s Tariff Pause
By Jack Phillips U.S. stock indexes surged on Wednesday afternoon following an announcement from President Donald Trump that he’ll pause...